ELTP (Elite Pharmaceuticals) EPS (Basic): $0.04 (TTM As of Dec. 2025)


ELTP Elite Pharmaceuticals Inc ELTP
42 GF Score
Price $0.39
GF Value $0.57
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals EPS (Basic)?

Elite Pharmaceuticals ELTP +4.08% 42 EPS (Basic) is $0.04 as of Dec. 2025. GuruFocus rates ELTP with a GF Score™ of 42/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review.

Elite Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was $0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04.

Elite Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2025 was $0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.

Elite Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2025 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.03.

During the past 12 months, Elite Pharmaceuticals's average EPS without NRIGrowth Rate was 2400.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Elite Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 125.70% per year. The lowest was -98.10% per year. And the median was 18.60% per year.

Elite Pharmaceuticals  (OTCPK:ELTP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Elite Pharmaceuticals EPS (Basic) Related Terms

Elite Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals EPS (Basic) Chart

Elite Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.00 0.02 0.00

Elite Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.02 -0.01 0.01 0.02
ELTP
42GF Score
Elite Pharmaceuticals Inc ELTP
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Elite Pharmaceuticals's Basic EPS for the fiscal year that ended in Mar. 2025 is calculated as

Basic EPS (A: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.315-0)/1068.290
=-0.00

Elite Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(18.594-0)/1074.115
=0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.04 mean?
Elite Pharmaceuticals (ELTP) has a EPS (Basic) of $0.04 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' EPS (Basic) too high?
Elite Pharmaceuticals' current EPS (Basic) is $0.04. Overall, Elite Pharmaceuticals has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' EPS (Basic) compare to SIGA and ORGO?
Elite Pharmaceuticals' EPS (Basic) of $0.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current EPS (Basic) is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.39 — trading 32.5% below its estimated fair value. The current EPS (Basic) is $0.04. Elite Pharmaceuticals' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current EPS (Basic) is $0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.39 is trading 32.5% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • EPS (Basic): $0.04
  • GF Value™: $0.57 vs. price of $0.39 (32.5% below fair value)
  • GF Score™: 42/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
42GF Score

Get the complete analysis for ELTP

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$0.57
GF Value